Division of Plastic and Reconstructive Surgery, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1X8.
Biotechnol Bioeng. 2013 May;110(5):1272-81. doi: 10.1002/bit.24800. Epub 2013 Jan 4.
The majority of bioengineering strategies to promote peripheral nerve regeneration after injury have focused on therapies to bridge large nerve defects while fewer therapies are being developed to treat other nerve injuries, such as nerve transection. We constructed delivery systems using fibrin gels containing either free GDNF or polylactide-glycolic acid (PLGA) microspheres with GDNF to treat delayed nerve repair, where ELISA verified GDNF release. We determined the formulation of microspheres containing GDNF that optimized nerve regeneration and functional recovery in a rat model of delayed nerve repair. Experimental groups underwent delayed nerve repair and treatment with GDNF microspheres in fibrin glue at the repair site or control treatments (empty microspheres or free GDNF without microspheres). Contractile muscle force, muscle mass, and MUNE were measured 12 weeks following treatment, where GDNF microspheres (2 weeks formulation) were superior compared to either no GDNF or short-term release of free GDNF to nerve. Nerve histology distal to the repair site demonstrated increased axon counts and fiber diameters due to GDNF microspheres (2 weeks formulation). GDNF microspheres partially reversed the deleterious effects of chronic nerve injury, and recovery was slightly favored with the 2 weeks formulation compared to the 4 weeks formulation.
大多数促进损伤后周围神经再生的生物工程策略都集中在治疗大的神经缺损的疗法上,而较少的疗法被开发用于治疗其他神经损伤,如神经横断。我们构建了使用含有游离 GDNF 或载有 GDNF 的聚乳酸-乙醇酸(PLGA)微球的纤维蛋白凝胶的递药系统,以治疗延迟性神经修复,其中 ELISA 验证了 GDNF 的释放。我们确定了含有 GDNF 的微球配方,该配方优化了大鼠延迟性神经修复模型中的神经再生和功能恢复。实验组在修复部位接受延迟性神经修复和 GDNF 微球纤维蛋白胶治疗,或接受对照治疗(空微球或无微球的游离 GDNF)。治疗 12 周后测量收缩肌肉力量、肌肉质量和运动单位数量,其中 GDNF 微球(2 周配方)优于无 GDNF 或游离 GDNF 的短期释放,对神经有更好的效果。修复部位远端的神经组织学显示,由于 GDNF 微球(2 周配方)的存在,轴突计数和纤维直径增加。GDNF 微球部分逆转了慢性神经损伤的有害影响,与 4 周配方相比,2 周配方的恢复略有优势。